(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCV)

(19) World Intellectual Property Organization

International Bureau



I IDDIA BANDON IN BINNO ARKI RONI, BAND DIRIK KI NI BAND BINN NIKA BAND BAND BINN BIN DIRIKA BIN BINDA BIND BAN

(43) International Publication Date 24 June 2004 (24.06.2004)

(10) International Publication Number WO 2004/052930 A2

C07K 14/705, (51) International Patent Classification⁷: 14/54, 7/08, A61K 39/385, 9/127, 47/48

(21) International Application Number:

PCT/DK2003/000859

(22) International Filing Date:

11 December 2003 (11.12.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: DK 11 December 2002 (11.12.2002) PA 2002 01893 11 December 2002 (11.12.2002) US 60/432,532 12 February 2003 (12.02.2003) DK PA 2003 00198 US 12 February 2003 (12.02.2003) 60/446,707

(71) Applicant (for all designated States except US): PHARMEXA A/S [DK/DK]; Kogle Allé 6, DK-2970 Hørsholm (DK).

(72) Inventor; and

(75) Inventor/Applicant (for US only): MOURITSEN, Søren [DK/DK]; c/o Pharmexa A/S, Kogle Allé 6, DK-2970 Hørsholm (DK).

- (74) Agent: INSPICOS A/S; Bøge Allé 3, P.O. Box 45, DK-2970 Hørsholm (DK).
- (81) Designated States (national): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, EG, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TARGETING SINGLE EPITOPES

(57) Abstract: The invention relates to novel immunogenic agents that are capable of inducing specific B-cell immunity directed against one single epitope present in a self-antigen. The immunogenic agent is a chimeric binding protein that binds specifically to a first receptor, said first receptor being one that binds a second receptor present in an antigen of an animal, wherein said chimeric binding protein comprises: (a) a B-cell epitope in the form of a binding site that specifically binds the first receptor and which competes with the second receptor for binding to the first receptor, (b) a scaffold protein structure being autologous in said mammal, and (c) at least one tolerance breaking amino acid sequence, which is heterologous in said animal and which binds to an MHC Class II molecule in said animal. In preferred embodiments, the chimeric binding protein is in the form of an anti-idiotypic antibody having a tolerance-breaking aminoacid sequence introduced. The invention further relates to methods of preparing the immunogens and methods of using the immunogens in therapy. Also, the invention relates to proteins, nucleic acid fragments, recombinantly modified host cells and virus that are useful in the practice of the methods of the invention.



(19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 24 June 2004 (24.06.2004)

(10) International Publication Number WO 2004/052930 A3

(51) International Patent Classification7: C07K 14/705. 14/54, 7/08, A61K 39/385, 9/127, 47/48

(21) International Application Number:

PCT/DK2003/000859

(22) International Filing Date:

11 December 2003 (11.12.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

11 December 2002 (11.12.2002) PA 2002 01893 DK US 60/432.532 11 December 2002 (11.12.2002) 12 February 2003 (12.02.2003) DK PA 2003 00198 US 60/446,707 12 February 2003 (12.02.2003)

(71) Applicant (for all designated States except US): PHARMEXA A/S [DK/DK]; Kogle Allé 6, DK-2970 Hørsholm (DK).

(72) Inventor; and

- (75) Inventor/Applicant (for US only): MOURITSEN, Søren [DK/DK]; c/o Pharmexa A/S, Kogle Allé 6, DK-2970 Hørsholm (DK).
- (74) Agent: INSPICOS A/S; Bøge Allé 3, P.O. Box 45, DK-2970 Hørsholm (DK).

(81) Designated States (national): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, EG, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report: 29 July 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TARGETING SINGLE EPITOPES



(57) Abstract: The invention relates to novel immunogenic agents that are capable of inducing specific B-cell immunity directed against one single epitope present in a self-antigen. The immunogenic agent is a chimeric binding protein that binds specifically to a first receptor, said first receptor being one that binds a second receptor present in an antigen of an animal, wherein said chimeric binding protein comprises: (a) a B-cell epitope in the form of a binding site that specifically binds the first receptor and which competes with the second receptor for binding to the first receptor, (b) a scaffold protein structure being autologous in said

mammal, and (c) at least one tolerance breaking amino acid sequence, which is heterologous in said animal and which binds to an MHC Class II molecule in said animal. In preferred embodiments, the chimeric binding protein is in the form of an anti-idiotypic antibody having a tolerance-breaking aminoacid sequence introduced. The invention further relates to methods of preparing the immunogens and methods of using the immunogens in therapy. Also, the invention relates to proteins, nucleic acid fragments, recombinantly modified host cells and virus that are useful in the practice of the methods of the invention.



Internacial Application No PCT/DK 03/00859

A CLASSIFICATION OF SUBJECT MATTER IPC 7 C07K14/705 C07K14/54 A61K47/48

C07K7/08

A61K39/385

A61K9/127

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

 $\begin{array}{ll} \text{Minimum documentation searched (classification system followed by classification symbols)} \\ IPC 7 C07K A61K \end{array}$

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, MEDLINE, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the	Relevant to claim No.			
E	US 2003/228324 A1 (LUND GARRY 11 December 2003 (2003-12-11) claim 8	ET AL)	1-56		
P,X	WO 03 042244 A (BRATT TOMAS ;KL (DK); PHARMEXA AS (DK); VOLDBOR 22 May 2003 (2003-05-22) claims 1-48	1-56			
X	WO 97 26784 A (ALEXANDER JEFFER ;DEFREES SHAWN (US); CYTEL CORP SETTE AL) 31 July 1997 (1997-07 claims 1-35	1-56			
X	WO 99 58658 A (EPIMMUNE INC) 18 November 1999 (1999-11-18) claim 40	-/	27-31		
X Furt	her documents are listed in the continuation of box C.	X Patent family members are listed	ìn annex.		
"A" docum	ategories of cited documents :	"T" later document published after the int or priority date and not in conflict with cited to understand the principle or the	ernational filing date the application but leory underlying the		
considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed		invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family			
Date of the actual completion of the international search		Date of mailing of the international search report			
1	l9 April 2004	1 7. 05. 20	1 7. 05. 2004		
Name and	malling address of the ISA European Patent Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer FERNANDO FARIETA /ELY			



International Application No
PCT/DK 03/00859

2.15	Alena DOMINENTO CONCIDEDED TO DE DEL EVANT	FC1/BK 03/00033
C.(Continu Category °	ation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01 41741 A (CELIS ESTEBAN ;SIDNEY JOHN (US); CHESNUT ROBERT (US); EPIMMUNE INC) 14 June 2001 (2001-06-14) claims 1-39; example 7	21
X	LA ROSA CORINNA ET AL: "Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice." BLOOD. UNITED STATES 15 NOV 2002, vol. 100, no. 10, 15 November 2002 (2002-11-15), pages 3681-3689, XP002277230 ISSN: 0006-4971 table 1	21
A	VOGEL M ET AL: "Mimicry of human IgE epitopes by anti-idiotypic antibodies." JOURNAL OF MOLECULAR BIOLOGY. ENGLAND 19 MAY 2000, vol. 298, no. 5, 19 May 2000 (2000-05-19), pages 729-735, XP002277231 ISSN: 0022-2836 figures 1-5	1-56
A	WEATHINGTON NATHANIEL M ET AL: "Rational design of peptide vaccines for autoimmune disease: harnessing molecular recognition to fix a broken network." EXPERT REVIEW OF VACCINES. ENGLAND FEB 2003, vol. 2, no. 1, February 2003 (2003-02), pages 61-73, XP002277232 ISSN: 1476-0584 figure 3	1-56
P,A	US 2003/185845 A1 (BRATT TOMAS ET AL) 2 October 2003 (2003-10-02) claims 1-48	1-56
A	WO 95 17212 A (CORRADIN GIAMPIETRO ;HEALY FRANK (CH); MACH JEAN PIERRE (CH); BOEH) 29 June 1995 (1995-06-29) claims 1-11	1-56
A	WO 95 05849 A (ELSNER HENRIK ; MOURITSEN & ELSNER A S (DK); MOURITSEN SOEREN (DK)) 2 March 1995 (1995-03-02) claims 1-9	1-56
А	WO 95 07707 A (CYTEL CORP) 23 March 1995 (1995-03-23) claims 1-17	1-56

INTERNATIONAL SEARCH REPORT

International application No. PCT/DK 03/00859

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This inte	ernational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X	Claims Nos.: 48-49, 55-56 because they relate to subject matter not required to be searched by this Authority, namely: see FURTHER INFORMATION sheet PCT/ISA/210
2. X	Claims Nos.: Part of 1-25,27-33,35-36,38-47,50-54 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically: see FURTHER INFORMATION sheet PCT/ISA/210
з. 🗓	Claims Nos.: 26, 34, 37 because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This into	ernational Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remar	k on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/ DK 03/00859

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Claims Nos.: 48-49, 55-56

Claims 48-49 and 55-56 relate to methods of treatment of the human or animal body by surgery or by therapy or diagnostic methods practised on the human or animal body (PCT Rule 39.1(iv)). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds or compositions.

Continuation of Box I.2

Claims Nos.: Part of 1-25,27-33,35-36,38-47,50-54

Part of present claims 1-25, 27-33, 35-36, 38-47, 50-54 relate to proteins, vectors, cells, compositions and methods defined by reference to desirable characteristics or properties of a "chimeric binding protein", which comprises three parts, namely:

a- Epitope (B-cell), that binds specifically and/or competitively, b- Scaffold protein structure, that stabilizes the 3D conformation, c- At least one "tolerance breaking amino acid sequence", that binds to an MHC class II molecule.

The claims cover all possible proteins, vectors, cells, compositions and methods having these characteristics or properties, whereas the application provides support within the meaning of Article 6 PCT and / or disclosure within the meaning of Article 5 PCT for only a very limited number of such proteins, vectors, cells, compositions and methods. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the proteins, vectors, cells, compositions and methods by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the proteins, vectors, cells, compositions and methods, those prepared in example 1 (only example) and part of claim 21 (part of sequences C.tetani/Padre).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a

INTERNATIONAL SEARCH REPORT

International Application No. PCT/ DK 03/00859

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210					
preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.					



Internacional Application No PCT/DK 03/00859

					DK 03/00039
Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 2003228324	A1	11-12-2003	US US	2003211114 A1 6541007 B1	13-11-2003 01-04-2003
WO 03042244	Α	22-05-2003	WO US	03042244 A2 2003185845 A1	22-05-2003 02-10-2003
WO 9726784	A	31-07-1997	AT AU BR CA CN DE DK EP PT WO US	220687 T 1582797 A 9710404 A 2242878 A1 1214051 A 69714011 D1 69714011 T2 876398 T3 0876398 A1 2177927 T3 2000504328 T 876398 T 9726784 A1 6413935 B1	15-08-2002 20-08-1997 17-08-1999 31-07-1997 14-04-1999 22-08-2002 27-02-2003 12-08-2002 11-11-1998 16-12-2002 11-04-2000 31-12-2002 31-07-1997 02-07-2002
WO 9958658	А	18-11-1999	AU CA EP JP WO US US US	4078599 A 2331846 A1 1078092 A2 2002520000 T 9958658 A2 6534482 B1 2003216342 A1 2003220285 A1 2003203869 A1 2003216343 A1	29-11-1999 18-11-1999 28-02-2001 09-07-2002 18-11-1999 18-03-2003 20-11-2003 27-11-2003 20-11-2003 20-11-2003
WO 0141741	Α	14-06-2001	US AU CA EP JP WO US	6602510 B1 2273701 A 2393730 A1 1242049 A1 2003516344 T 0141741 A1 2003224036 A1	05-08-2003 18-06-2001 14-06-2001 25-09-2002 13-05-2003 14-06-2001 04-12-2003
US 2003185845	A1	02-10-2003	WO	03042244 A2	22-05-2003
WO 9517212	Α	29-06-1995	EP AU WO	0659438 A1 1317695 A 9517212 A1	10-07-1995
WO 9505849	A	02-03-1995	AT AU AU CA DE DE WO EP ES GR	162723 T 707083 B2 7009198 A 7608094 A 2170236 A1 69408342 D1 69408342 T2 9505849 A1 752886 T3 0752886 A1 2112559 T3	30-07-1998 21-03-1995 02-03-1995 05-03-1998 14-05-1998 02-03-1995 04-05-1998 15-01-1997 01-04-1998



International Application No PCT/DK 03/00859

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9505849	A	JP 9505031 T US 2002090379 A1	20-05-1997 11-07-2002
WO 9507707	A 23-03-19	95 AU 698962 B2 AU 7873694 A CN 1135181 A EP 0735893 A1 JP 9505559 T WO 9507707 A1 US 5736142 A US 6413935 B1	12-11-1998 03-04-1995 06-11-1996 09-10-1996 03-06-1997 23-03-1995 07-04-1998 02-07-2002